m6A Regulator and Potential Drug Response

General Information of the m6A Regulator (ID: REG00015)
Regulator Name Protein virilizer homolog (VIRMA)
Synonyms
KIAA1429; MSTP054
    Click to Show/Hide
Gene Name VIRMA
Regulator Type WRITER ERASER READER
Regulator Link Click to View Full Information of This Regulator
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Cyclin-dependent kinase 1 (CDK1)
P-276 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for P-276. The Protein virilizer homolog (VIRMA) has potential in affecting the response of P-276 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [2]
P276-00 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for P276-00. The Protein virilizer homolog (VIRMA) has potential in affecting the response of P276-00 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [3]
Ro 31-7453 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Ro 31-7453. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Ro 31-7453 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [4]
Roscovitine [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Roscovitine. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Roscovitine through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [5]
AG-024322 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for AG-024322. The Protein virilizer homolog (VIRMA) has potential in affecting the response of AG-024322 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [6]
PHA-793887 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for PHA-793887. The Protein virilizer homolog (VIRMA) has potential in affecting the response of PHA-793887 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [3]
RGB-286638 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for RGB-286638. The Protein virilizer homolog (VIRMA) has potential in affecting the response of RGB-286638 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [3]
L-751250 [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for L-751250. The Protein virilizer homolog (VIRMA) has potential in affecting the response of L-751250 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [3]
ON-01135 [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for ON-01135. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ON-01135 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [7]
(2,6-Diamino-pyridin-3-yl)-phenyl-methanone [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for (2,6-Diamino-pyridin-3-yl)-phenyl-methanone. The Protein virilizer homolog (VIRMA) has potential in affecting the response of (2,6-Diamino-pyridin-3-yl)-phenyl-methanone through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [8]
10Z-Hymenialdisine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 10Z-Hymenialdisine. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 10Z-Hymenialdisine through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [9]
2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [10]
3,4-bis(indol-3-yl)maleimide derivative [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 3,4-bis(indol-3-yl)maleimide derivative. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3,4-bis(indol-3-yl)maleimide derivative through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [8]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [11]
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [11]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [12]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [11]
4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [13]
4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [14]
4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [15]
9-Nitropaullone [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 9-Nitropaullone. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 9-Nitropaullone through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [16]
aloisine A [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for aloisine A. The Protein virilizer homolog (VIRMA) has potential in affecting the response of aloisine A through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [17]
alsterpaullone 2-cyanoethyl [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for alsterpaullone 2-cyanoethyl. The Protein virilizer homolog (VIRMA) has potential in affecting the response of alsterpaullone 2-cyanoethyl through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [17]
aminopurvalanol A [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for aminopurvalanol A. The Protein virilizer homolog (VIRMA) has potential in affecting the response of aminopurvalanol A through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [18]
AZAKENPAULLONE [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for AZAKENPAULLONE. The Protein virilizer homolog (VIRMA) has potential in affecting the response of AZAKENPAULLONE through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [19]
Bisindolylmaleimide-I [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Bisindolylmaleimide-I. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [19]
BMS-265246 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for BMS-265246. The Protein virilizer homolog (VIRMA) has potential in affecting the response of BMS-265246 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [17]
Cdk1 inhibitor [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Cdk1 inhibitor. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Cdk1 inhibitor through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [20]
CGP74514A [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for CGP74514A. The Protein virilizer homolog (VIRMA) has potential in affecting the response of CGP74514A through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [7]
CVT-313 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for CVT-313. The Protein virilizer homolog (VIRMA) has potential in affecting the response of CVT-313 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [21]
IN1535 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for IN1535. The Protein virilizer homolog (VIRMA) has potential in affecting the response of IN1535 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [22]
Indirubin-3'-monoxime [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Indirubin-3'-monoxime. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Indirubin-3'-monoxime through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [23]
Indirubin-5-sulfonate [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Indirubin-5-sulfonate. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Indirubin-5-sulfonate through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [24]
JNJ 7706621 [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for JNJ 7706621. The Protein virilizer homolog (VIRMA) has potential in affecting the response of JNJ 7706621 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [11]
K00024 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for K00024. The Protein virilizer homolog (VIRMA) has potential in affecting the response of K00024 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [25]
Microxine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Microxine. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Microxine through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [26]
NU6140 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for NU6140. The Protein virilizer homolog (VIRMA) has potential in affecting the response of NU6140 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [27]
PF-228 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for PF-228. The Protein virilizer homolog (VIRMA) has potential in affecting the response of PF-228 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [14]
Purvalanol A [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Purvalanol A. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Purvalanol A through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [7]
Quinoxaline1 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Quinoxaline1. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Quinoxaline1 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [17]
RO-316233 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for RO-316233. The Protein virilizer homolog (VIRMA) has potential in affecting the response of RO-316233 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [8]
SU9516 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for SU9516. The Protein virilizer homolog (VIRMA) has potential in affecting the response of SU9516 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [28]
Thieno analogue of kenpaullone [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Thieno analogue of kenpaullone. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Thieno analogue of kenpaullone through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [15]
BAY 10-00394 [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for BAY 10-00394. The Protein virilizer homolog (VIRMA) has potential in affecting the response of BAY 10-00394 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [29]
CGP-60474 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for CGP-60474. The Protein virilizer homolog (VIRMA) has potential in affecting the response of CGP-60474 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [30]
Olomoucine [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Olomoucine. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Olomoucine through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [31]
R547 [Discontinued in Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for R547. The Protein virilizer homolog (VIRMA) has potential in affecting the response of R547 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [3]
SCH 727965 [Discontinued in Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for SCH 727965. The Protein virilizer homolog (VIRMA) has potential in affecting the response of SCH 727965 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [32]
ZK 304709 [Discontinued in Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for ZK 304709. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ZK 304709 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [3]
Cyclin-dependent kinase 4 (CDK4)
Apremilast [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Apremilast. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Apremilast through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [34]
LY2835219 [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for LY2835219. The Protein virilizer homolog (VIRMA) has potential in affecting the response of LY2835219 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [35]
Palbociclib [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Palbociclib. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Palbociclib through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [36]
Ribociclib Succinate [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Ribociclib Succinate. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Ribociclib Succinate through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [37]
Trilaciclib [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Trilaciclib. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Trilaciclib through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [38]
LEE011 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for LEE011. The Protein virilizer homolog (VIRMA) has potential in affecting the response of LEE011 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [39]
FCN-437 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for FCN-437. The Protein virilizer homolog (VIRMA) has potential in affecting the response of FCN-437 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [40]
G1T38 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for G1T38. The Protein virilizer homolog (VIRMA) has potential in affecting the response of G1T38 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [41]
GLR2007 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for GLR2007. The Protein virilizer homolog (VIRMA) has potential in affecting the response of GLR2007 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [3], [33]
P-276 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for P-276. The Protein virilizer homolog (VIRMA) has potential in affecting the response of P-276 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [42]
P276-00 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for P276-00. The Protein virilizer homolog (VIRMA) has potential in affecting the response of P276-00 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [5], [33]
Ro 31-7453 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Ro 31-7453. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Ro 31-7453 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [43]
AG-024322 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for AG-024322. The Protein virilizer homolog (VIRMA) has potential in affecting the response of AG-024322 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [43]
FN-1501 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for FN-1501. The Protein virilizer homolog (VIRMA) has potential in affecting the response of FN-1501 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [44]
G1T28-1 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for G1T28-1. The Protein virilizer homolog (VIRMA) has potential in affecting the response of G1T28-1 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [43]
P1446A-05 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for P1446A-05. The Protein virilizer homolog (VIRMA) has potential in affecting the response of P1446A-05 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [34]
PF-07220060 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PF-07220060. The Protein virilizer homolog (VIRMA) has potential in affecting the response of PF-07220060 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [45]
PHA-793887 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PHA-793887. The Protein virilizer homolog (VIRMA) has potential in affecting the response of PHA-793887 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [46]
RGB-286638 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for RGB-286638. The Protein virilizer homolog (VIRMA) has potential in affecting the response of RGB-286638 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [3], [33]
INOC-005 [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for INOC-005. The Protein virilizer homolog (VIRMA) has potential in affecting the response of INOC-005 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [3], [33]
1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [47]
1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [47]
1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [11], [33]
1-Pyridin-2-yl-3-quinolin-5-yl-urea [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 1-Pyridin-2-yl-3-quinolin-5-yl-urea. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 1-Pyridin-2-yl-3-quinolin-5-yl-urea through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [47]
10-hydroxy-18-methoxybetaenone [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 10-hydroxy-18-methoxybetaenone. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 10-hydroxy-18-methoxybetaenone through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [43]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [11], [33]
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [48]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [49]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [11], [33]
Cdk4 inhibitor III [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Cdk4 inhibitor III. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Cdk4 inhibitor III through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [50]
Fascaplysin [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Fascaplysin. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Fascaplysin through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [51]
K00024 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for K00024. The Protein virilizer homolog (VIRMA) has potential in affecting the response of K00024 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [52]
N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide. The Protein virilizer homolog (VIRMA) has potential in affecting the response of N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [53]
NSC-625987 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for NSC-625987. The Protein virilizer homolog (VIRMA) has potential in affecting the response of NSC-625987 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [54]
NU-6102 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for NU-6102. The Protein virilizer homolog (VIRMA) has potential in affecting the response of NU-6102 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [55]
NU6140 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for NU6140. The Protein virilizer homolog (VIRMA) has potential in affecting the response of NU6140 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [27], [33]
PYRAZOLOPYRIDAZINE 1 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PYRAZOLOPYRIDAZINE 1. The Protein virilizer homolog (VIRMA) has potential in affecting the response of PYRAZOLOPYRIDAZINE 1 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [51]
PYRAZOLOPYRIDAZINE 2 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The Protein virilizer homolog (VIRMA) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [47]
Ro-0505124 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Ro-0505124. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Ro-0505124 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [56]
BAY 10-00394 [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for BAY 10-00394. The Protein virilizer homolog (VIRMA) has potential in affecting the response of BAY 10-00394 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [57]
CYC-103 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for CYC-103. The Protein virilizer homolog (VIRMA) has potential in affecting the response of CYC-103 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [50]
PD-0183812 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PD-0183812. The Protein virilizer homolog (VIRMA) has potential in affecting the response of PD-0183812 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [33], [43]
R547 [Discontinued in Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for R547. The Protein virilizer homolog (VIRMA) has potential in affecting the response of R547 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [3], [33]
ZK 304709 [Discontinued in Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for ZK 304709. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ZK 304709 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [3], [33]
Death-associated protein kinase 3 (DAPK3)
URMC-099 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Death-associated protein kinase 3 (DAPK3) is a therapeutic target for URMC-099. The Protein virilizer homolog (VIRMA) has potential in affecting the response of URMC-099 through regulating the expression of Death-associated protein kinase 3 (DAPK3). [58], [59]
E2F3 messenger RNA (E2F3 mRNA)
ISIS 114170 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary E2F3 messenger RNA (E2F3 mRNA) is a therapeutic target for ISIS 114170. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 114170 through regulating the expression of E2F3 messenger RNA (E2F3 mRNA). [33], [60]
ISIS 114184 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary E2F3 messenger RNA (E2F3 mRNA) is a therapeutic target for ISIS 114184. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 114184 through regulating the expression of E2F3 messenger RNA (E2F3 mRNA). [33], [60]
ISIS 114197 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary E2F3 messenger RNA (E2F3 mRNA) is a therapeutic target for ISIS 114197. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 114197 through regulating the expression of E2F3 messenger RNA (E2F3 mRNA). [33], [60]
ISIS 114232 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary E2F3 messenger RNA (E2F3 mRNA) is a therapeutic target for ISIS 114232. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 114232 through regulating the expression of E2F3 messenger RNA (E2F3 mRNA). [33], [61]
G1/S-specific cyclin-D1 (CCND1)
ABT-263 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for ABT-263. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ABT-263 through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [33], [62]
Briciclib [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for Briciclib. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Briciclib through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [33], [42]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [11], [33]
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [11], [33]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [33], [63]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [11], [33]
7-hydroxycoumarin [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 7-hydroxycoumarin. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 7-hydroxycoumarin through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [33], [55]
Helicase-moi messenger RNA (DICER1 mRNA)
ISIS 138612 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138612. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 138612 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA). [64], [65]
ISIS 138613 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138613. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 138613 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA). [64], [65]
ISIS 138616 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138616. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 138616 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA). [64], [65]
ISIS 138647 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138647. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 138647 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA). [64], [65]
ISIS 138648 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138648. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 138648 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA). [64], [65]
ISIS 138649 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138649. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 138649 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA). [64], [65]
ISIS 138678 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Helicase-moi messenger RNA (DICER1 mRNA) is a therapeutic target for ISIS 138678. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 138678 through regulating the expression of Helicase-moi messenger RNA (DICER1 mRNA). [64], [66]
Hexokinase-2 (HK2)
VDA-1102 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hexokinase-2 (HK2) is a therapeutic target for VDA-1102. The Protein virilizer homolog (VIRMA) has potential in affecting the response of VDA-1102 through regulating the expression of Hexokinase-2 (HK2). [67], [68]
NAD-dependent deacetylase sirtuin-1 (SIRT1)
GSK2245840 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for GSK2245840. The Protein virilizer homolog (VIRMA) has potential in affecting the response of GSK2245840 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [70]
MB-12066 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for MB-12066. The Protein virilizer homolog (VIRMA) has potential in affecting the response of MB-12066 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [71]
SEN-196 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for SEN-196. The Protein virilizer homolog (VIRMA) has potential in affecting the response of SEN-196 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [72]
SRT2379 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for SRT2379. The Protein virilizer homolog (VIRMA) has potential in affecting the response of SRT2379 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [73]
SRT3025 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for SRT3025. The Protein virilizer homolog (VIRMA) has potential in affecting the response of SRT3025 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [74]
(R)-sirtinol [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for (R)-sirtinol. The Protein virilizer homolog (VIRMA) has potential in affecting the response of (R)-sirtinol through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [75]
(S)-sirtinol [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for (S)-sirtinol. The Protein virilizer homolog (VIRMA) has potential in affecting the response of (S)-sirtinol through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [75]
2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for 2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [76]
2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [77]
Meta-sirtinol [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for Meta-sirtinol. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Meta-sirtinol through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [78]
Para-sirtinol [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for Para-sirtinol. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Para-sirtinol through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [75]
RO-316233 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for RO-316233. The Protein virilizer homolog (VIRMA) has potential in affecting the response of RO-316233 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [76]
Ro31-8220 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for Ro31-8220. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Ro31-8220 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [79]
splitomicin [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for splitomicin. The Protein virilizer homolog (VIRMA) has potential in affecting the response of splitomicin through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [80]
SRT1720 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for SRT1720. The Protein virilizer homolog (VIRMA) has potential in affecting the response of SRT1720 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [75]
YK-3237 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for YK-3237. The Protein virilizer homolog (VIRMA) has potential in affecting the response of YK-3237 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [79]
GSK184072 [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for GSK184072. The Protein virilizer homolog (VIRMA) has potential in affecting the response of GSK184072 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). [69], [81]
Transcription factor AP-1 (JUN)
DCB-3503 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transcription factor AP-1 (JUN) is a therapeutic target for DCB-3503. The Protein virilizer homolog (VIRMA) has potential in affecting the response of DCB-3503 through regulating the expression of Transcription factor AP-1 (JUN). [82], [83]
ISIS 10582 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transcription factor AP-1 (JUN) is a therapeutic target for ISIS 10582. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ISIS 10582 through regulating the expression of Transcription factor AP-1 (JUN). [82], [84]
Pergularinine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transcription factor AP-1 (JUN) is a therapeutic target for Pergularinine. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Pergularinine through regulating the expression of Transcription factor AP-1 (JUN). [82], [84]
PNRI-299 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transcription factor AP-1 (JUN) is a therapeutic target for PNRI-299. The Protein virilizer homolog (VIRMA) has potential in affecting the response of PNRI-299 through regulating the expression of Transcription factor AP-1 (JUN). [82], [85]
TAM-67 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transcription factor AP-1 (JUN) is a therapeutic target for TAM-67. The Protein virilizer homolog (VIRMA) has potential in affecting the response of TAM-67 through regulating the expression of Transcription factor AP-1 (JUN). [82], [86]
TWS-119 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transcription factor AP-1 (JUN) is a therapeutic target for TWS-119. The Protein virilizer homolog (VIRMA) has potential in affecting the response of TWS-119 through regulating the expression of Transcription factor AP-1 (JUN). [82], [87]
T-5224 [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transcription factor AP-1 (JUN) is a therapeutic target for T-5224. The Protein virilizer homolog (VIRMA) has potential in affecting the response of T-5224 through regulating the expression of Transcription factor AP-1 (JUN). [42], [82]
Wee1-like protein kinase (WEE1)
MK-1775 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Wee1-like protein kinase (WEE1) is a therapeutic target for MK-1775. The Protein virilizer homolog (VIRMA) has potential in affecting the response of MK-1775 through regulating the expression of Wee1-like protein kinase (WEE1). [88], [89]
ZN-c3 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Wee1-like protein kinase (WEE1) is a therapeutic target for ZN-c3. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ZN-c3 through regulating the expression of Wee1-like protein kinase (WEE1). [88], [90]
9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Wee1-like protein kinase (WEE1) is a therapeutic target for 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione through regulating the expression of Wee1-like protein kinase (WEE1). [88], [91]
References
Ref 1 KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner. Oncogene. 2019 Aug;38(33):6123-6141. doi: 10.1038/s41388-019-0861-z. Epub 2019 Jul 8.
Ref 2 Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci. 2005 Aug;62(15):1763-71. doi: 10.1007/s00018-005-5185-1.
Ref 3 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. doi: 10.1038/nrd2907.
Ref 4 P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34. doi: 10.1158/1535-7163.MCT-06-0614.
Ref 5 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
Ref 6 A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle. 2011 Mar 15;10(6):963-70. doi: 10.4161/cc.10.6.15075. Epub 2011 Mar 15.
Ref 7 Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem. 2004 May 7;279(19):20267-76. doi: 10.1074/jbc.M312381200. Epub 2004 Feb 26.
Ref 8 Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22. doi: 10.1016/s0960-894x(98)00163-2.
Ref 9 First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307. doi: 10.1021/jm800977q.
Ref 10 Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41. doi: 10.1016/j.bmcl.2006.04.071. Epub 2006 May 6.
Ref 11 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. doi: 10.1021/jm0580297.
Ref 12 Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52. doi: 10.1074/jbc.M606695200. Epub 2007 Mar 28.
Ref 13 Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors. J Med Chem. 2005 Mar 24;48(6):1886-900. doi: 10.1021/jm040099a.
Ref 14 Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86. doi: 10.1016/j.ejmech.2009.10.002. Epub 2009 Oct 13.
Ref 15 4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70. doi: 10.1016/j.bmcl.2007.04.021. Epub 2007 Apr 10.
Ref 16 M-phase regulation of the recruitment of mRNAs onto polysomes using the CDK1/cyclin B inhibitor aminopurvalanol. Biochem Biophys Res Commun. 2003 Jul 11;306(4):880-6. doi: 10.1016/s0006-291x(03)01083-0.
Ref 17 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. doi: 10.1073/pnas.0708800104. Epub 2007 Dec 11.
Ref 18 A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. Mol Cancer Ther. 2011 Feb;10(2):242-54. doi: 10.1158/1535-7163.MCT-10-0720. Epub 2011 Jan 7.
Ref 19 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. doi: 10.1016/j.bmcl.2003.10.062.
Ref 20 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11. doi: 10.1021/jm050267e.
Ref 21 Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37. doi: 10.1158/1535-7163.MCT-05-0022.
Ref 22 The kinase inhibitor indirubin-3'-oxime prevents germinal vesicle breakdown and reduces parthenogenetic development of pig oocytes. Theriogenology. 2006 Mar 1;65(4):744-56. doi: 10.1016/j.theriogenology.2005.05.054. Epub 2005 Aug 18.
Ref 23 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 24 SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2. Biochem Biophys Res Commun. 2003 Oct 24;310(3):1026-31. doi: 10.1016/j.bbrc.2003.09.114.
Ref 25 2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. Bioorg Med Chem Lett. 1999 Jan 4;9(1):91-6. doi: 10.1016/s0960-894x(98)00691-x.
Ref 26 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2005 May 2;15(9):2221-4. doi: 10.1016/j.bmcl.2005.03.024.
Ref 27 Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30. doi: 10.1021/jm0256169.
Ref 28 Microxine, a new cdc2 kinase inhibitor from the Australian marine sponge Microxina species. J Nat Prod. 2001 Apr;64(4):525-6. doi: 10.1021/np000546z.
Ref 29 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. doi: 10.1093/nar/gkm958. Epub 2007 Nov 29.
Ref 30 Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res. 2013; 3(3): 323-338.
Ref 31 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014). Expert Opin Ther Pat. 2015;25(9):953-70. doi: 10.1517/13543776.2015.1045414. Epub 2015 Jul 13.
Ref 32 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. doi: 10.2337/diabetes.52.3.588.
Ref 33 Identification of pathology-specific regulators of m(6)A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine. EPMA J. 2020 Jul 29;11(3):485-504. doi: 10.1007/s13167-020-00220-3. eCollection 2020 Sep.
Ref 34 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 35 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 36 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
Ref 37 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014). Expert Opin Ther Pat. 2015;25(8):849-72. doi: 10.1517/13543776.2015.1039984. Epub 2015 May 19.
Ref 38 Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
Ref 39 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
Ref 40 Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
Ref 41 Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82. doi: 10.1158/1078-0432.CCR-13-1675. Epub 2013 Sep 17.
Ref 42 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 43 Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. doi: 10.1155/2011/483154. Epub 2010 Dec 27.
Ref 44 Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
Ref 45 Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. doi: 10.1021/acs.jmedchem.7b01261. Epub 2018 Feb 12.
Ref 46 ClinicalTrials.gov (NCT04557449) Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4). U.S. National Institutes of Health.
Ref 47 Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27. doi: 10.1021/jm0103256.
Ref 48 Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4. Bioorg Med Chem. 2008 Aug 15;16(16):7728-39. doi: 10.1016/j.bmc.2008.07.002. Epub 2008 Jul 8.
Ref 49 Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J Med Chem. 2006 Sep 7;49(18):5470-7. doi: 10.1021/jm060216x.
Ref 50 Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. doi: 10.1016/s0165-6147(02)02071-0.
Ref 51 N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. J Med Chem. 2004 Sep 9;47(19):4716-30. doi: 10.1021/jm040063i.
Ref 52 The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999 Dec;5(12):4279-86.
Ref 53 Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45. doi: 10.1021/np9905259.
Ref 54 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg Med Chem Lett. 2000 Mar 6;10(5):461-4. doi: 10.1016/s0960-894x(00)00014-7.
Ref 55 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. doi: 10.1021/jm0605740.
Ref 56 Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9. doi: 10.1016/j.bmcl.2008.10.075. Epub 2008 Oct 22.
Ref 57 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1976).
Ref 58 VIRMA contributes to non-small cell lung cancer progression via N(6)-methyladenosine-dependent DAPK3 post-transcriptional modification. Cancer Lett. 2021 Dec 1;522:142-154. doi: 10.1016/j.canlet.2021.08.027. Epub 2021 Sep 11.
Ref 59 Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2015 Oct;33(5):1086-92. doi: 10.1007/s10637-015-0273-z. Epub 2015 Aug 14.
Ref 60 US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression.
Ref 61 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 62 New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(alpha-azolylbenzyl)-1H-indoles. Bioorg Med Chem Lett. 1999 Feb 8;9(3):333-6. doi: 10.1016/s0960-894x(98)00737-9.
Ref 63 Clinical pipeline report, company report or official report of Onconova.
Ref 64 The m(6)A-methylase complex recruits TREX and regulates mRNA export. Sci Rep. 2018 Sep 14;8(1):13827. doi: 10.1038/s41598-018-32310-8.
Ref 65 US patent application no. 7,427,470, Antisense modulation of helicase-moi expression.
Ref 66 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 67 N(6)-methyladenosine methyltransferase KIAA1429 elevates colorectal cancer aerobic glycolysis via HK2-dependent manner. Bioengineered. 2022 May;13(5):11923-11932. doi: 10.1080/21655979.2022.2065952.
Ref 68 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2019).
Ref 69 m(6)A methyltransferase KIAA1429 acts as an oncogenic factor in colorectal cancer by regulating SIRT1 in an m(6)A-dependent manner. Cell Death Discov. 2022 Feb 25;8(1):83. doi: 10.1038/s41420-022-00878-w.
Ref 70 Pharmacological activation of Sirt1 ameliorates polyglutamine-induced toxicity through the regulation of autophagy. PLoS One. 2013 Jun 10;8(6):e64953. doi: 10.1371/journal.pone.0064953. Print 2013.
Ref 71 Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
Ref 72 Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52. doi: 10.1002/acn3.135. Epub 2014 Oct 31.
Ref 73 The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391. doi: 10.1371/journal.pone.0134391. eCollection 2015.
Ref 74 Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen. 2011 Dec;16(10):1153-69. doi: 10.1177/1087057111422103. Epub 2011 Nov 15.
Ref 75 Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005 Dec 1;48(24):7789-95. doi: 10.1021/jm050100l.
Ref 76 Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem. 2006 Dec 14;49(25):7307-16. doi: 10.1021/jm060118b.
Ref 77 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
Ref 78 Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem. 2005 Dec 15;48(25):8045-54. doi: 10.1021/jm050522v.
Ref 79 Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues. J Med Chem. 2010 Feb 11;53(3):1407-11. doi: 10.1021/jm9013345.
Ref 80 Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6. doi: 10.1038/nature06261.
Ref 81 SRT2379, a small-molecule SIRT1 activator, fails to reduce cytokine release in a human endotoxemia model. Critical Care 2013, 17(Suppl 4):P8.
Ref 82 KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in gastric cancer. J Cell Physiol. 2020 Oct;235(10):7420-7432. doi: 10.1002/jcp.29645. Epub 2020 Feb 13.
Ref 83 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity. Bioorg Med Chem. 2008 Sep 15;16(18):8745-59. doi: 10.1016/j.bmc.2008.07.041. Epub 2008 Jul 20.
Ref 84 Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4338-42. doi: 10.1016/j.bmcl.2007.05.021. Epub 2007 May 16.
Ref 85 AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001 May 17;20(22):2771-80. doi: 10.1038/sj.onc.1204377.
Ref 86 Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84. doi: 10.1038/nchembio0705-74.
Ref 87 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
Ref 88 KIAA1429 is a potential prognostic marker in colorectal cancer by promoting the proliferation via downregulating WEE1 expression in an m6A-independent manner. Oncogene. 2022 Jan;41(5):692-703. doi: 10.1038/s41388-021-02066-z. Epub 2021 Nov 24.
Ref 89 Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
Ref 90 National Cancer Institute Drug Dictionary (drug id 770319).
Ref 91 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. doi: 10.3892/or.2013.2329. Epub 2013 Mar 5.